Key result
Concurrent infection is not linked to lower decongestion rates in cardiorenal syndrome type 1.
Why the study?
Infections frequently precipitate ADHF and may alter decongestive trajectories, reduce diuretic efficacy, and increase kidney injury risk in CRS1, but their impact on decongestion and kidney outcomes remains unclear.
Does concurrent infection reduce successful decongestion or increase major adverse kidney events in patients with cardiorenal syndrome type 1?
Cohort (n=256)
No
Does concurrent infection reduce successful decongestion or increase major adverse kidney events in patients with cardiorenal syndrome type 1?
Answers are grounded in this paper and cite their sources.
In patients with cardiorenal syndrome type 1, concurrent infection is associated with more severe baseline congestion but does not impair the ability to achieve successful decongestion or increase short-term adverse kidney events.
Background Infections are frequent precipitants of acute decompensated heart failure (ADHF) and may alter decongestive trajectories in patients with cardiorenal syndrome type 1 (CRS1), it may reduce diuretic efficacy and increase the risk of kidney injury. However, the impact of infection on decongestion and kidney outcomes in CRS1 remains unclear. Methods We conducted a prospective cohort study including 256 patients with CRS1 hospitalized at a tertiary center (2022–2024). Patients were stratified by the presence of infection, defined as clinical suspicion plus antibiotic therapy. The primary outcome was successful decongestion, assessed by symptoms, biomarkers (BNP/CA-125), and POCUS findings. Secondary outcomes included major adverse kidney events at 10 and 30 days (MAKE: death, kidney replacement therapy [KRT], or ≥25% eGFR decline). Results Seventy-two patients (28.1%) had infection, presenting with higher BNP (13,405 vs. 25,264 pg/mL, p = 0.012) and lower PaO 2 (45 vs. 65.5 mmHg, p = 0.019). Furosemide exposure was comparable (600 vs. 580 mg, p = 0.62). Successful decongestion occurred in 61.4% of patients with infection vs. 59.8% without infection (p = 0.83). Infection was not independently associated with decongestion (aOR 1.28, 95% CI 0.65–2.51) or MAKE-30 (aOR 1.26, 95% CI 0.57–2.79). Conclusions In CRS1, infection was associated with more severe baseline congestion but did not compromise decongestion rates or increase short-term MAKE. These findings support the notion that achieving decongestion is feasible in patients with ADHF due to infection without an incremental risk of MAKE.
No takes yet. Share an insight, caveat, or question.
Chávez-Íñiguez et al. (2026) conducted a cohort in Cardiorenal syndrome type 1 (n=256). Infection vs. No infection was evaluated on Successful decongestion (aOR 1.28, 95% CI 0.65-2.51, p=0.48). In patients with cardiorenal syndrome type 1, concurrent infection was not independently associated with lower odds of achieving successful decongestion compared to those without infection.
Synapse has enriched 10 related papers. Consider them for comparative context: